MedTrace Logo

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

NCT01686334 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-03-12

No results posted yet for this study

Summary

The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell vaccination can significantly prevent relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease.

Conditions

Interventions

BIOLOGICAL

DC vaccine

Autologous WT1 mRNA-electroporated DCs

Sponsors & Collaborators

  • Kom Op Tegen Kanker

    collaborator OTHER

  • Stichting tegen Kanker

    collaborator OTHER

  • Research Foundation Flanders

    collaborator OTHER

  • Zwi Berneman

    lead OTHER

Principal Investigators

  • Zwi Berneman, MD, PhD · University Hospital, Antwerp

  • Evelien LJ Smits, MSc, PhD · Universiteit Antwerpen

  • Sébastien Anguille, MD, PhD · University Hospital, Antwerp

  • Ann Van de Velde, MD, PhD · University Hospital, Antwerp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01686334 on ClinicalTrials.gov